ST Pharm, a Korean drugmaker, said it has signed a supply agreement for RNA manufacturing with Quantoom Biosciences, a Belgium-based company specializing in RNA technology platform development.

Under the agreement, ST Pharm will supply its in-vitro transcription (IVT)-based mRNA-LNP platform and proprietary 5’-capping reagent, SmartCap, to Quantoom Biosciences, which will integrate them into its mRNA production platforms -- Ntensity and Ncapsulate.

This partnership seeks to combine the strengths of both companies to provide comprehensive solutions in the RNA manufacturing market, expanding their global influence.

The two companies expect that the collaboration will accelerate the development and production of innovative RNA-based therapeutics by leveraging the companies' respective technologies more effectively.

"We are delighted to make significant progress in the field of RNA therapeutics through our partnership with Quantoom Biosciences," ST Pharm CEO Sung Moo-je said. "This collaboration marks an important milestone in our mission to deliver advanced RNA technology to the global market."

By combining the strengths of the two companies, ST Pharm hopes to accelerate the development of life-changing RNA-based therapies, Sung added.

Quantoom Biosciences CEO José Castillo also said, "The collaboration with ST Pharm represents a pivotal moment for our Ntensity platform."

By securing ST Pharm's unique technology, the company is now able to offer its customers unprecedented flexibility and control in the mRNA production process, Castillo added.